Review Article
Pharmacoacupuncture for Idiopathic Parkinson’s Disease: A Systematic Review of Randomized Controlled Trials

Ki-Ho Cho,1 Tae-Hun Kim,2 Woo-Sang Jung,1 Sang-Kwan Moon,1 Chang-Nam Ko,1 Seung-Yeon Cho,1 Chan-Yong Jeon,3 Tae Young Choi,4 Myeong Soo Lee,4 Sang-Ho Lee,5 Eun Kyoung Chung,6 and Seungwon Kwon1

1Department of Cardiology and Neurology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea
2Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, Republic of Korea
3Department of Korean Internal Medicine, College of Korean Medicine, Gachon University, Seongnam, Republic of Korea
4Clinical Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea
5Gangdong Mokhuri Oriental Medical Hospital, Department of Internal Medicine, Seoul, Republic of Korea
6Division of Clinical Pharmacy, Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea

Correspondence should be addressed to Seungwon Kwon; kkkokkottung@hanmail.net

Received 22 December 2017; Revised 3 April 2018; Accepted 17 April 2018; Published 25 June 2018

Academic Editor: Carmen Mannucci

Copyright © 2018 Ki-Ho Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Pharmacoacupuncture is a new acupuncture treatment that stimulates acupuncture points by injecting herbal medicine into them. Recently, pharmacoacupuncture has been widely used in the treatment of idiopathic Parkinson’s disease in traditional East Asian medicine. The purpose of this systematic review is to evaluate the efficacy and safety of pharmacoacupuncture in the treatment of idiopathic Parkinson’s disease. 

Methods. The following electronic databases were searched for studies published in or before December 2016: Medline, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, OASIS, and CNKI, without language restriction. The main outcome assessed was the total Unified Parkinson’s Disease Rating Scale (UPDRS) score. The details of the pharmacoacupuncture intervention, such as the herbal medicine and acupuncture points used, were also investigated.

Results. From 138 studies, 3 randomized controlled trials were included; the number of patients analyzed was 134. Most of the studies showed considerable methodological flaws. There was heterogeneity of the intervention type and treatment duration in the included studies. Therefore, we could not conduct a meta-analysis. In one study, adjunctive bee venom pharmacoacupuncture therapy significantly improved total UPDRS scores compared with conventional therapy alone. Another study, which used adjunctive Kakkonein pharmacoacupuncture, did not reveal significant improvement compared with conventional therapy alone. A third study reported that Mailuoning pharmacoacupuncture was able to significantly improve the modified Webster Symptom Score when compared with no treatment. Adverse events related to the pharmacoacupuncture were reported in only one case, itching caused by the bee venom.

Conclusions. Our findings regarding the efficacy of pharmacoacupuncture as a therapy for idiopathic Parkinson’s disease are currently inconclusive. Further large and rigorous clinical trials are needed.

1. Introduction

Idiopathic Parkinson’s disease (IPD) is one of the most common chronic degenerative brain diseases. In the early stages, there are four major motor symptoms: bradykinesia, resting tremor, rigidity, and postural instability [1]. Thereafter, there are various nonmotor symptoms, such as neuropsychiatric symptoms, with chronic progression [1]. The hallmarks of IPD are progressive reduction in the number of dopaminergic neurons in the substantia nigra and continuous reduction of blood dopamine levels. The typical therapy for IPD with this pathology is pharmacotherapy, which takes the form of dopamine-elevating drugs, such as levodopa and dopamine agonists. Although these pharmacologic treatments initially
show good efficacy, long-term levodopa therapy can cause on-off, peak-dose dyskinesia, and impulsive disorders as side effects [2]. Surgical procedures, such as deep brain stimulation (DBS), have also been attempted. However, DBS has potential neuropsychiatric side effects, such as apathy, cognitive dysfunction, and personality disorder [3], and carries additional risks, such as cerebral hemorrhage during surgery and postoperative brain edema [4]. Therefore, as the duration of treatment increases, most patients tend to seek alternative therapies. One study reported that 25.6–76% of patients were using complementary and alternative therapies [5].

In East Asian countries, besides typical alternative medical treatment, such as acupuncture and herbal medicine, a new form of acupuncture combining acupuncture with herbal medicine, called pharmacoacupuncture, [6] is being utilized in patients with IPD. Similar to traditional acupuncture, pharmacoacupuncture stimulates acupuncture points. In contrast to traditional acupuncture, pharmacoacupuncture injects herbal medicine extract with neuroprotective, antioxidant, and microcirculatory effects into acupuncture points, which are known to be beneficial to patients with IPD. It is believed that a synergistic effect may be achieved through the simultaneous use of herbal medicine and acupuncture; this technique is widely used in patients with IPD in East Asian countries, such as Korea. However, there has been no systematic review or meta-analysis to assess the efficacy of pharmacoacupuncture for IPD. The objectives of this review were to assess the clinical evidence on the efficacy and safety of pharmacoacupuncture in patients with IPD compared with conventional therapy alone or no treatment by using randomized controlled trials (RCTs).

2. Methods

2.1. Search Strategy and Selection Criteria. We followed the methods of Lee et al. (2016) [7]. To evaluate the efficacy of pharmacoacupuncture (acupuncture point injection) in IPD, two independent authors (Seungwon Kwon and Tae-Hun Kim) searched for RCTs published in the following databases prior to December 2016: Medline, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL), which are English databases; the Chinese National Knowledge Infrastructure (CNKI; http://www.cnki.net), which is a Chinese database; and the Oriental Medicine Advanced Searching Integrated System (OASIS; https://oasis.kiom.re.kr), which is a Korean database. There were no language restrictions in this review. Each search strategy was modified according to the characteristics of the individual databases; however, primary search terms were “Parkinson disease” and “Acupuncture point injection.” Details of the employed search strategies are described in Supplementary Material (available here).

2.2. Eligibility Criteria. Eligible participants were defined as patients with IPD. Parkinson-plus syndromes and secondary Parkinsonism caused by drugs or toxins were exclusion criteria. Qualified clinical diagnosis methods, including the Queens Square clinical diagnostic criteria and the American Academy of Neurology practice parameters, were used for the diagnosis of IPD. There were no restrictions based on gender, ethnicity, symptom severity, disease duration, and clinical setting. Only the acupuncture point injection-type of pharmacoacupuncture intervention was included in this study. The intravenous injection-type of pharmacoacupuncture intervention was excluded. In addition, we excluded studies that combined pharmacoacupuncture with drug therapies other than conventional therapies for IPD. The application of pharmacoacupuncture was defined as a single treatment or combined treatment with conventional treatments, including anti-Parkinsonian medication or DBS. Control groups varied, with some receiving no treatment and others receiving only conventional treatments. We excluded studies involving other forms of pharmacoacupuncture, including manual acupuncture, electroacupuncture, and herbal medicine administered orally. We also excluded conventional interventions combined with alternative therapies such as herbal medicine, various other forms of acupuncture, or moxibustion.

2.3. Outcome Assessment. The primary outcome assessed was Unified Parkinson’s Disease Rating Scale (UPDRS) scores. Secondary outcomes were total effective rate (TER) and modified Webster Symptom Scores. TER was defined as the percent of patients who showed improvement of their symptoms during treatment.

2.4. Data Extraction. Data extraction was assessed by two researchers (Seungwon Kwon and Ki-Ho Cho) and an arbiter (Tae-Hun Kim) made the final decision if there was disagreement between the researchers. Data recorded in a predefined extraction form included treatment protocol (intervention of pharmacoacupuncture group or control group), numbers of patients, country of publication, Parkinson’s disease duration (years), outcome, and adverse events. Pharmacoacupuncture treatment details, such as treatment duration and frequency, acupuncture points used, and concomitant interventions, were extracted. If any of the above data was unclear, efforts were made to contact the authors of the study.

2.5. Assessment of Risk of Bias. Risk of bias (ROB) assessment was conducted by two independent authors (Seungwon Kwon and Ki-Ho Cho). In the event of a disagreement while extracting data or assessing ROB, the third author (Tae-Hun Kim) resolved the discrepancy. The domains of ROB assessment are random sequence generation, allocation concealment, participant and personnel blinding, outcome assessment blindness, incomplete data, selective reporting, and other biases according to the Cochrane Handbook for Systematic Reviews [8]. Each domain was graded as high, low, or unclear.

3. Results

3.1. Description of the Included Studies. One hundred and thirty-eight studies were identified. One hundred and eight studies were assessed for eligibility after screening and removing duplications (Figure 1). Of these, 18 were excluded
Records identified through database searching: MEDLINE, EMBASE, CENTRAL, OASIS (n = 85)  

Additional records identified through CNKI (n = 53)  

Records after duplicates were removed (n = 23)  

Records screened (n = 108)  

Records screened (n = 108)  

Full-text articles assessed for eligibility (n = 27)  

Full-text articles excluded, with reasons (n = 24)  
- Inappropriate design (n = 13)  
- Inappropriate intervention (n = 8)  
- Inappropriate population (n = 1)  
- Duplicate (n = 2)  

Studies included in qualitative synthesis (n = 3)  

FIGURE 1: Study flowchart.

due to inappropriate intervention (not related to pharmacoacupuncture), population (not related to IPD), or study design (in vivo or in vitro studies and review articles). Three studies were ultimately chosen for this review. One RCT was conducted in South Korea [9], and two were conducted in China [10, 11]. One study was published in English [9], and the others [10, 11] were published in Chinese. The total number of patients analyzed in the review was 134 (pharmacoacupuncture group, 76; control group, 58). A summary of the included articles is presented in Table 1.

3.2. Details of the Included Intervention and Outcome Assessment. There were two intervention and control therapy types: (1) pharmacoacupuncture with conventional therapy versus conventional therapy alone [9, 10] and (2) pharmacoacupuncture versus no treatment [11]. In one trial where bee venom pharmacoacupuncture on GB20, LI11, GB34, ST36, and LR3 was used [9], severity of IPD symptoms was evaluated using UPDRS score. Patients with median IPD duration of 5 years were included. TER was used to evaluate the effect of Kakkonein pharmacoacupuncture on IPD symptoms in another RCT [10]. Kakkonein injection on bilateral GB20 was administered to patients with IPD with duration of 5.8 ± 2.5 years. Modified Webster Symptoms Score was used in remaining RCT [11]. In this RCT, Mailuoning injection was administered to bilateral ST36 and GB34. IPD duration [11] was 6.3 ± 2.0 years in the pharmacoacupuncture group and 6.7 ± 1.8 in the control group.

3.3. Risk of Bias in the Included Studies. The overall risk of bias was not low. In particular, the bias related to participant blinding was relatively high. A summary of the risk of bias is shown in Figure 2.

3.3.1. Random Sequence Generation. All three studies stated their use of a random number table [9–11].
| First author, year | Total numbers of patients: pharmacoacupuncture group/control group | Groups | Main outcomes (Pharmacoacupuncture/control) | Adverse event Types of AEs in pharmacoacupuncture group (n=)/control group (n=) |
|-------------------|---------------------------------------------------------------|--------|---------------------------------------------|--------------------------------------------------------------------------------|
| Cho, 2012         | 22: 13/9                                                      | Pharmacoacupuncture PD history (yrs) Protocol: 5.0 (median) | After 8 weeks: Total UPDRS 24.0 (median, 17.5, 35.0)/38.0 (17.5, 53.5) \( p < 0.05 \) calculated by Tukey’s HSD post hoc test | Itching in 1 case/0 (n = 14) |
|                   |                                                               | Control group PD history (yrs) Protocol: 5.0 (median) |                                                                                   |                                                                                   |
|                   |                                                               | Pharmacoacupuncture on bilateral GB20, LI11, GB34, ST36, LR3 + Antiparkinsonian medication |                                                                                   |                                                                                   |
|                   |                                                               | Control group + Antiparkinsonian medication |                                                                                   |                                                                                   |
|                   | Bee venom (twice a week for 8 weeks (16 total sessions))       |                                                                                   |                                                                                   |                                                                                   |
|                   | on bilateral GB20, LI11, GB34, ST36, LR3 + Antiparkinsonian medication |                                                                                   |                                                                                   |                                                                                   |
| Liu, 2015         | 79: 40/39                                                     | Pharmacoaupuncture PD history (yrs) Protocol: 5.8 \( \pm 2.5 \) | After 8 weeks: TER (\%): 90.0/84.6 -RR 1.06, 95% CI [0.90, 1.26] | No report |
|                   |                                                               | Control group PD history (yrs) Protocol: 6.0 \( \pm 3.1 \) |                                                                                   |                                                                                   |
|                   |                                                               | Pharmacoacupuncture Kakkonein (3 times a week for 8 weeks (24 total sessions)) on bilateral GB20 + Madopar |                                                                                   |                                                                                   |
|                   |                                                               | Control group + Madopar |                                                                                   |                                                                                   |
|                   | Madopar                                                       |                                                                                   |                                                                                   |                                                                                   |
| Xu, 2002          | 33: 23/10                                                     | Pharmacoaupuncture PD history (yrs) Protocol: 6.7 \( \pm 1.8 \) | After 15 days: Modified Webster Symptom Scores 13.26 \( \pm 4.00/20.20 \pm 5.75 \) -MD −6.94, 95% CI [−10.86, −3.02] | No report |
|                   |                                                               | Control group PD history (yrs) Protocol: 6.3 \( \pm 2.0 \) |                                                                                   |                                                                                   |
|                   |                                                               | Pharmacoacupuncture Mailuoning (7 times a week for 15 days (15 total sessions)) on bilateral ST36, GB34 |                                                                                   |                                                                                   |
|                   |                                                               | Control group + Madopar |                                                                                   |                                                                                   |
|                   | Madopar                                                       |                                                                                   |                                                                                   |                                                                                   |

PD: Parkinson’s disease; AEs: adverse events; UPDRS: Unified Parkinson’s Disease Rating Scale; TER: total effective rate; RR: risk ratio; CI: confidence interval; MD: mean difference.
3.3.2. Allocation Concealment. Only one study reported that group allocation was done by an independent researcher [10]. The other two studies did not report their method of allocation concealment. The ROB for these studies was graded as unclear.

3.3.3. Blinding of Participants and Personnel. None of the studies used a placebo pharmacoacupuncture device in order to blind participants [9–11]. Therefore, all these studies were graded as having high ROB.

3.3.4. Blinding of Outcome Assessment. Two studies blinded the assessor [9,10]. The other study [11] was graded as unclear because its description of assessor blinding was unclear.

3.3.5. Incomplete Outcome Data. In one study [9], nine patients dropped out. Eight patients dropped out in another study [10]. However, the difference in dropout numbers between the two groups was not large, and the causes were similar; therefore these studies were graded as having low ROB. In another study [11], there were no drop-outs. This study was graded as having low ROB.

3.3.6. Selective Reporting. We could not find published protocols for the included studies, but all of the variables mentioned in Methods were reported in Results. Therefore, all studies were graded as low ROB.

3.3.7. Other Biases. There were no clues with which to evaluate other biases, so all studies were graded as unclear.

3.4. Outcome. None of the studies could be pooled into a quantitative analysis due to clinical heterogeneity in the intervention types and outcome assessments.

3.4.1. Bee Venom Pharmacoacupuncture. Cho et al. [9] reported that 8 weeks of bee venom pharmacoacupuncture treatment in combination with anti-Parkinsonian medication for patients with IPD improved total UPDRS score (mean (lower quartile, upper quartile); 24.0 (17.5, 35.0) in the bee venom group, 38.0 (17.5, 53.5) in the control group, $p < 0.05$) (Table 1).

3.4.2. Kakkonein Pharmacoacupuncture. Liu et al. [10] reported that TER of 8 weeks of Kakkonein pharmacoacupuncture treatment in combination with Madopa—compared to Madopa alone—was not significantly different (risk ratio (RR) 1.06, 95% confidence interval (CI) [0.90, 1.26]) (Table 1).

3.4.3. Mailuoning Pharmacoacupuncture. Xu et al. [11] reported that 8 weeks of Mailuoning pharmacoacupuncture treatment—compared to no treatment—significantly improved total modified Webster Symptom Score (mean difference (MD) $-6.94, 95\%$ CI $[-10.86, -3.02]$) (Table 1).

3.5. Adverse Events. Only the RCT [9] using bee venom injection described adverse events. Itching, which can be caused by bee venom injection, occurred in only 1 case in the bee venom group. No adverse events were mentioned in other trials [10,11] (Table 1).

4. Discussion

4.1. Summary of Main Findings. We conducted a systematic review of the clinical studies on the use of pharmacoacupuncture for treatment of IPD. Among the 138 studies identified through systematic searching, a total of three studies were included in this review, incorporating a total of 134 patients with IPD. Although every study showed high ROB in binding of participants, most domains had either low or unclear ROB. Due to the heterogeneity of both the outcome assessments and the content of the pharmacoacupuncture injections used in the studies, we could not conduct an effective meta-analysis. Therefore, we do not make a definitive conclusion about the effect of pharmacoacupuncture on IPD. From the analyzed studies, we see that adjunctive administration of bee venom pharmacoacupuncture significantly improves the total UPDRS score of patients with IPD when compared with conventional therapy alone [9], and adjunctive administration of Kakkonein pharmacoacupuncture tends to improve overall symptoms in patients with IPD; however, it was not significantly improved compared with conventional therapy alone [10]. Finally, Mailuoning pharmacoacupuncture was able to significantly improve IPD patients’ modified Webster Symptoms Score compared to no treatment [11]. Adverse events related to pharmacoacupuncture were reported in only one case, where itching was caused by administration of bee venom [9].

4.2. Strengths and Limitations of This Review. To our knowledge, this systematic review of the efficacy of pharmacoacupuncture in IPD treatment is the first of its kind. For the purpose of including as many literatures as possible, we did not impose any language restrictions on the studies
analyzed; this review includes trials from South Korea and China. However, there were some limitations to this study. Due to heterogeneous study designs, including different types of pharmacoacupuncture, treatment durations, and outcome variables, we could not assess the estimated effect of pharmacoacupuncture through meta-analysis. First, there were differences in the comparison subjects. In two studies [9, 10], conventional therapies were maintained and pharmacoacupuncture was used as an adjunctive therapy. In the other study [11], the effect of pharmacoacupuncture was compared with no treatment. Second, the types of extraction injected in each study were different. One study [9] used bee venom, the second [10] used Kakkonein, and the last study [11] used Mailuoning. Third, there was a difference in treatment duration. Both studies continued for 8 weeks [9, 10], while the remaining study continued for 15 days [11]. Finally, there was a difference in the outcome variables in included studies. UPDRS [9], TER [10], and modified Webster Symptoms Score [11] were used in three studies, respectively.

Furthermore, we could not give a definitive conclusion regarding the efficacy of pharmacoacupuncture due to a lack of studies that met our inclusion criteria and methodological flaws in the included studies. Among three studies [9–11] included in this review, no study applied placebo to the control group. Therefore, performance bias was high. Furthermore, in one study [11], it was unclear whether blinding of outcome assessors was available. These methodological flaws should be improved in the future studies.

4.3. Interpretation of the Findings and Implications for Further Study. Despite the development of both pharmacotherapy and surgical treatment (e.g., deep brain stimulation), there are still limitations to the treatment of most patients with Parkinson’s disease. Pharmacotherapy, specifically with levodopa, causes an on-off phenomenon or peak dose dyskinesia after 5 years of “honeymoon period,” which significantly reduces the quality of life of patients [2]. In addition, surgical treatment is not an option for many patients because the cost is relatively high and there is a danger of adverse events, such as cerebral hemorrhage, after the procedure [4]. Therefore, recently, the use of various traditional and complementary medical therapies for the treatment of Parkinson’s disease has become an attractive option [5]. The most common treatment methods are herbal medicine and acupuncture. Pharmacoacupuncture combines these two treatments to inject herbal medicine extract directly into acupuncture points [6].

In this study, three types of pharmacoacupuncture were applied. The first utilized purified bee venom extracted by applying electromagnetic waves to Apis mellifera [12], the second technique, Kakkonein pharmacoacupuncture, used Kakkonein contained in Pueraria root, and the third treatment, Mailuoning pharmacoacupuncture, used a medicine called Mailuoning, which consists of Scrophulariae Radix, Dendrobii Herba, Achyranthis Radix, Lonicerae Flos, and Codonopsis pilosulae Radix.

The substances used in these pharmacoacupuncture therapies have documented neuroprotective effects. The primary outcome measure of our review is UPDRS score. This outcome was only evaluated in the trial involving administration of bee venom. This study confirmed that adjunctive application of bee venom pharmacoacupuncture could significantly improve total UPDRS scores. The mechanisms of action of bee venom in Parkinson’s disease are believed to be as follows [13]: (i) mitigation of neuroinflammation and microglial activation, (ii) suppression of apoptosis in dopaminergic neurons, (iii) protective effect against glutamate-induced neurotoxicity, and (iv) recovery of normal brain neurochemistry. Consistent with the proposed mechanisms of pharmacoacupuncture, 1 RCT [9] and 1 prospective open-label clinical study [14] have been published. Recently, an RCT using bee venom injection has been published [15].

In the other two studies, secondary outcomes, TER and the modified Webster Symptoms Score, were used to assess treatment effect. Although no significant effect was observed in the study where Kakkonein was administered [10], Kakkonein, which is one of the isoflavones of Puerarin, has anticholinergic effect and is likely to be a significant drug for Parkinson’s disease [16]. In the RCT using Mailuoning injectable solution, a 15-day treatment resulted in significant improvement in the modified Webster Symptoms Score of patients with Parkinson’s disease [11]. Mailuoning injection is a commonly used injection for acute ischemic stroke and is known to have a beneficial effect on neurological deficit [17]. In experimental and clinical pharmacological studies [17], it has been shown to improve blood circulation, prevent ischemic injury, and protect heart and brain tissue. In this study, Mailuoning injections were used as pharmacoacupuncture.

In pharmacoacupuncture, not only the injected solution but also the acupuncture points used are important. In this review, we saw that GB34, GB20, and ST36 were the most used. GB34 was used in 2 RCTs, GB20 was used in 2 RCTs, and ST36 was used in 2 RCTs. Of these, the acupuncture point with the most evidence of efficacy in Parkinson’s disease is GB34. GB34 has been reported to activate the precentral gyrus and prefrontal cortex in patients with Parkinson’s disease [18], and another study has shown activation of neural responses in the substantia nigra, caudate, thalamus, and putamen of Parkinson’s disease patients [19]. GB34 is thought to be helpful in improving Parkinson’s disease symptoms by increasing the activity of the brain area associated with the development of movement disorders in patients with Parkinson’s disease. ST36 has also been shown to have potential use in Parkinson’s disease. In a previous experimental study [20], electroacupuncture on ST36 and SP6 in a mouse model of Parkinson’s disease showed protective effects in the nigrostriatal system via antioxidative and antiapoptotic effects. In addition, a review of the effects of acupuncture on the adult brain [21] suggested that stimulation of ST36 could cause neurogenesis in the adult brain, although this effect may be specific to healthy individuals, even though it may be targeted to healthy subjects. Consequently, ST36 has the potential to prevent brain degenerative changes due to its antioxidant, antiapoptotic, and neurogenesis effects in Parkinson’s disease patients. Although GB20 is also one of the most widely used acupuncture points, we could not find any significant effect in this review. There is also a lack of previous studies to support the effects of GB20. Therefore, based on our analysis, future clinical studies should investigate the effects
of bee venom or Mailuoning as an injection and GB34 and ST36 as acupuncture points.

In contrast with the other two studies [9, 11], no statistically significant effect was observed in the Kakkonein injection study [10]. There are two assumed reasons. (i) Kakkonein is known to have an anticholinergic effect [16]. However, the anticholinergic agents are currently used only as an adjunct in the treatment of Parkinson's disease. Therefore, there is a possibility that the effect of Kakkonein was limited due to its pharmacological properties. (ii) Only one acupuncture point, GB20, was used in this study. On the other hand, two other studies [9, 11] used 2 to 5 acupuncture points that could affect motor symptoms of Parkinson's disease. Therefore, in contrast with procedures performed at clinical sites, where multiple acupuncture points are used at once, the effect in this study might be limited.

4.4. Conclusion. In this review, we found few clinical studies on the effects of pharmacoaupuncture in Parkinson's disease, and meta-analysis could not be performed due to the heterogeneity of the interventions used in these studies. Therefore, we cannot make a concrete conclusion about the effect of pharmacoaupuncture on Parkinson's disease. However, from this review, we can derive recommendations for the types of injections and acupuncture points that could be used in future clinical studies. Future studies should include larger clinical trials with unified injectable solutions and unified acupuncture points to prevent intervention heterogeneity. In addition, as noted in this review, consideration of blinding is also important to improve ROB.

Acknowledgments

This study was supported by a grant of the Traditional Korean Medicine R&D Program, funded by the Ministry of Health & Welfare through the Korea Health Industry Development Institute (KHIDI, HBl6C0051).

Supplementary Materials

Search strategies in each database. (Supplementary Materials)

References

[1] S. Sveinbjörnsdottir, “The clinical symptoms of Parkinson’s disease,” Journal of Neurochemistry, pp. 318–324, 2016.
[2] M. F. Bastide, W. G. Meissner, B. Picconi et al., “Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease,” Progress in Neurobiology, vol. 132, pp. 96–168, 2015.
[3] D. J. Burn and A. I. Tröster, “Neuropsychiatric complications of medical and surgical therapies for parkinson’s disease,” Journal of Geriatric Psychiatry and Neurology, vol. 17, no. 3, pp. 172–180, 2004.
[4] C. K. Park, N. Y. Jung, M. Kim, and J. W. Chang, “Analysis of delayed intracerebral hemorrhage associated with deep brain stimulation surgery,” World Neurosurgery, vol. 104, pp. 537–544, 2017.
[5] Y. Wang, C.-L. Xie, W.-W. Wang et al., “Epidemiology of complementary and alternative medicine use in patients with Parkinson’s disease,” Journal of Clinical Neuroscience, vol. 20, no. 8, pp. 1062–1067, 2013.
[6] J. Park, H. Lee, B.-C. Shin, M. S. Lee, B. Kim, and J.-I. Kim, “Pharmacopuncture in Korea: a systematic review and meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 4683121, pp. 1–19, 2016.
[7] H. Lee, T.-H. Kim, and J. Leem, “Acupuncture for heart failure: a systematic review of clinical studies,” International Journal of Cardiology, vol. 222, pp. 321–331, 2016.
[8] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., “The cochrane collaboration’s tool for assessing risk of bias in randomised trials,” British Medical Journal, vol. 343, no. 7829, Article ID d5928, 2011.
[9] S.-Y. Cho, S.-R. Shim, H. Y. Rhee et al., “Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson’s disease,” Parkinsonism & Related Disorders, vol. 18, no. 8, pp. 948–952, 2012.
[10] C.-H. Liu, R. Wang, Y.-B. Jin, Z.-L. Sun, X. Zhou, and J.-Y. He, “Acupoint injection of kakkonein for early- or mid-stage Parkinson’s disease: a multicenter randomized controlled clinical trial,” Zhongguo Yi Xue Ke Xue Yuan Yi Xue Qing Bao Yan Jiu Suo Bian Ji, vol. 40, no. 1, pp. 56–60, 2015.
[11] B. Xu, C. Ma, and G. Z. Chen, “The influence of acupuncture injection on central monoamine transmitters in Parkinson’s disease,” Shanghai J Acu-mox, vol. 21, no. 2, pp. 1-2, 2002.
[12] K. Nam, K. Je, J. H. Lee et al., “Inhibition of COX-2 activity and proinflammatory cytokines (TNF-α and IL-1β) production by water-soluble sub-fractionated parts from bee (Apis mellifera) venom,” Archives of Pharmacal Research, vol. 26, no. 5, pp. 383–388, 2003.
[13] K. Awad, A. I. Abushouk, A. H. AbdelKarim, M. Mohammed, A. Negida, and A. S. Shalash, “Bee venom for the treatment

Abbreviations

CENTRAL: Cochrane Central Register of Controlled Trials
CNKI: Chinese National Knowledge Infrastructure
DBS: Deep brain stimulation
IPD: Idiopathic Parkinson’s disease
OASIS: Oriental Medicine Advanced Searching Integrated System
RCTs: Randomized controlled trials
ROB: Risk of bias
TER: Total effective rate
UPDRS: Unified Parkinson’s Disease Rating Scale

Disclosure

An earlier version of this study has been presented as an abstract in XXIII WCN (World Congress of Neurology) 2017.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All research was done by the authors.
of Parkinson's disease: how far is it possible?" *Biomedicine & Pharmacotherapy*, vol. 91, pp. 295–302, 2017.

[14] K.-H. Doo, J.-H. Lee, S.-Y. Cho et al., "A prospective open-label study of combined treatment for idiopathic Parkinson's disease using acupuncture and bee venom acupuncture as an adjunctive treatment," *The Journal of Alternative and Complementary Medicine*, vol. 21, no. 10, pp. 598–603, 2015.

[15] A. Hartmann, J. Müllner, N. Meier et al., "Bee venom for the treatment of Parkinson disease - A randomized controlled clinical trial," *PLoS ONE*, vol. 11, no. 7, Article ID e0158235, 2016.

[16] H. Y. Zhang, D. W. Li, and C. H. Shi, "Advances in studies on clinical practice of puerarin," *Drugs & Clinic*, vol. 19, no. 2, pp. 247–250, 2012.

[17] W. Yang, Z. Shi, H. Yang, J. Teng, J. Zhao, and G. Xiang, "Mailuoning for acute ischaemic stroke," *Cochrane Database of Systematic Reviews*, vol. 1, Article ID CD007028, 2015.

[18] S. Yeo, I.-H. Choe, M. van den Noort et al., "Acupuncture on GB34 activates the precentral gyrus and prefrontal cortex in Parkinson's disease," *BMC Complementary and Alternative Medicine*, vol. 14, article 336, 2014.

[19] S. Yeo, S. Lim, I.-H. Choe et al., "Acupuncture stimulation on GB34 activates neural responses associated with parkinson's disease," *CNS Neuroscience & Therapeutics*, vol. 18, no. 9, pp. 781–790, 2012.

[20] H. Wang, Y. Pan, B. Xue et al., "The antioxidative effect of electro-acupuncture in a mouse model of Parkinson's disease," *PLoS ONE*, vol. 6, no. 5, Article ID e19790, 2011.

[21] M. H. Nam, K. S. Ahn, and S. H. Choi, "Acupuncture stimulation induces neurogenesis in adult brain," *International Review of Neurobiology*, vol. 111, pp. 67–90, 2013.